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ABSTRACT
Patients with axial spondyloarthritis (axSpA)
frequently report pain, stiffness, fatigue, and
sleep problems, which may lead to impaired
physical activity. The majority of reported-on
measures evaluating physical activity and sleep
disturbance in axSpA are self-reported question-
naires, which can be impacted by patient recall
(reporting bias). One objective measure,
polysomnography, has been employed to eval-
uate sleep in patients with axSpA; however, it is
an intrusive measure and cannot be used over
the long term. More convenient objective mea-
sures are therefore needed to allow for the long-
term assessment of both sleep and physical
activity in patients’ daily lives. Wearable tech-
nology that utilizes actigraphy is increasingly
being used for the objective measurement of
physical activity and sleep in various therapy
areas, as it is unintrusive and suitable for con-
tinuous tracking to allow longitudinal assess-
ment. Actigraphy characterizes sleep disruption
as restless movement while sleeping, which is
particularly useful when studying conditions
such as axSpA in which chronic pain and dis-
comfort due to stiffness may be evident. Studies
have also shown that actigraphy can effectively
assess the impact of disease on physical activity.
More research is needed to establish the useful-
ness of objective monitoring of sleep and phys-
ical activity specifically in axSpA patients over
time. This review summarizes the current per-
spectives on physical activity and sleep quality in
patients with axSpA, and the possible role of
actigraphy in the future to more accurately
evaluate the impact of treatment interventions
on sleep and physical activity in axSpA.
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Key Summary Points
Patients with axial spondyloarthritis
(axSpA) frequently report pain, stiffness,
fatigue, and sleep problems, which may
lead to impaired physical activity
The majority of measures for sleep and
physical activity used in this patient
population are subjective and limited by
patient recall, reporting bias, and
relatively short study intervals
Actigraphy will enable unintrusive and
objective monitoring of sleep and physical
activity in patients with axSpA over longer
periods of time
Importantly, actigraphy may be used to
evaluate the impact of treatment
interventions on physical activity and
sleep, allowing for identification of
appropriate management strategies in
patients with axSpA
Enhanced insight into sleep disturbance
and impaired physical activity, and
association with treatment changes in the
long term, will enable healthcare
providers to better understand patient
variability and identify potential
opportunities to address axSpA-related
drivers of sleep disturbance and physical
inactivity
PLAIN LANGUAGE SUMMARY
Axial spondyloarthritis is a type of inflamma-
tory arthritis. It mainly affects the spine, but
can also affect peripheral joints, tendons, and
ligaments. Over time, the spine can become
progressively stiff and painful due to the
inflammation caused by the immune system’s
attack. Symptoms often improve with exercise,
and therefore a key component of the man-
agement and treatment of axSpA is physical
activity. However, levels of physical activity are
often lower in those with axSpA, and this can
have a negative impact on pain, function, and
sleep quality.
To appropriately support people with axSpA,
we need to understand the long-term effects of
reduced physical activity and disturbed sleep.
One way to do this is to measure physical
activity and sleep, and here we look at the ways
we can measure both of these in people with
axSpA. This includes the use of tools such as
questionnaires and wearable technology or
devices, similar to Fitbits or pedometers. We
particularly focus on wearable technology and
how it may be used to assess the impact of dif-
ferent treatments on sleep and physical activity
in people with axSpA.
INTRODUCTION
Axial spondyloarthritis (axSpA) is an inflam-
matory arthritis of the sacroiliac joints and
spine, commonly presenting with chronic back
pain [1]. Subgroups of axSpA include the pro-
totype ankylosing spondylitis (AS), which is
defined by the presence of definite radiographic
sacroiliitis (also known as radiographic axSpA)
[1], and non-radiographic axSpA (nr-axSpA),
which represents an early form of the disease
with a low to no burden of radiographic damage
[2, 3]. The 1984 modified New York classifica-
tion criteria for AS use conventional radio-
graphs of the sacroiliac joints to assess structural
damage [4], whereas the Assessment of
SpondyloArthritis international Society (ASAS)
classification criteria for axSpA, developed in
2009, can be used to classify axSpA even in the
absence of sacroiliac joint damage on radio-
graphs [5]. As axSpA refers to a spectrum of
disease, this review will use this terminology
throughout; however, it should be noted that
most of the studies covered in this review
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focused on patients with AS, whereas more
recent cohorts include patients with nr-axSpA.
Pain, stiffness, fatigue, and disturbed sleep
are major concerns in patients with axSpA [6],
and are associated with impaired physical
activity. Studies show that poor sleep is related
to depressed mood and increased stress [7], and
correlates with poor quality of life, pain, and
disease activity in patients with axSpA [8]. The
location and spread of pain with axSpA have
also been shown to be different between gen-
ders and are related to worse clinical outcomes,
with women experiencing increased pain in the
thoracic and cervicothoracic junction body
regions [9].
This review explores the current literature
concerning the methods used to evaluate
physical activity—defined as any bodily move-
ment produced by skeletal muscles that results
in energy expenditure, of which exercise is just
one component—and sleep in axSpA, including
subjective and objective measures. The use of
wearable technology [10] and how this will aid
our future understanding of sleep and physical
activity in patients with axSpA will also be a
focus.
METHODS
Literature and Search Strategy
An author kick-off call led to the development
of a top-line manuscript outline, on which
authors submitted references deemed of inter-
est. Following this, a focused PubMed literature
search was performed March 12, 2018. Only
articles published in English were included. The
data were not limited by a publication date
range. Searches included terms such as ‘‘physi-
cal activity,’’ ‘‘sleep,’’ ‘‘ankylosing spondylitis,’’
‘‘axial spondyloarthritis,’’ ‘‘pain,’’ and ‘‘actigra-
phy.’’ The full text of relevant articles was
evaluated for specific data relating to sleep and
physical activity in patients with axSpA, and the
technology involved. Only those deemed of
relevance to the objectives of this study were
included.
Compliance with Ethics Guidelines
This article is a literature review based on pre-
viously conducted studies. All procedures per-
formed in studies involving human participants
that were cited in this review were in accor-
dance with the ethical standards of the institu-
tional and/or national research committee and
with the 1964 Helsinki Declaration and its later
amendments or comparable ethical standards,
as reported in the primary reports.
RESULTS
Current Perspectives on Physical Activity
in axSpA
The benefits of physical activity for the man-
agement of axSpA have long been recognized;
regular exercise was recommended in the first
set of Assessment of SpondyloArthritis Interna-
tional Society–European League Against
Rheumatism (ASAS–EULAR) guidelines devel-
oped in 2006 [11]. In a Cochrane review, exer-
cise and physical activity demonstrated small
beneficial effects on physical function, spinal
mobility, and patient global assessments in
axSpA [12]. Another systematic review found
that therapeutic exercise improved physical
function, disease activity, pain, stiffness, joint
mobility, and cardiovascular performance in
adult patients with axSpA [13]. A systematic
review also evaluated the impact of an aerobic
fitness program over standard physiotherapy on
disease activity and functional status in axSpA
[14]. The meta-analysis showed no additional
benefit of aerobic exercise over standard phys-
iotherapy in terms of Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI) and
Bath Ankylosing Spondylitis Functional Index
(BASFI) scores [14]. Finally, in a multicenter,
randomized trial of 100 axSpA patients, a
12-week high-intensity cardiorespiratory and
strength exercise program reduced disease
activity, as assessed by Ankylosing Spondylitis
Disease Activity Score (ASDAS) and BASDAI, and
improved both physical function, as assessed by
BASFI, and cardiovascular health, as measured
by maximal test on a treadmill walking uphill
Rheumatol Ther (2019) 6:487–501 489
until exhaustion according to the modified
Balke protocol (peak oxygen uptake: VO2peak
ml/kg/min), in patients with axSpA [15].
Although the efficacy of physical activity for
axSpA is well documented, there is much less
information available for nr-axSpA. In a study
of 46 patients with axSpA who underwent a
6-month education and intensive exercise pro-
gram, similar clinical efficacy was observed in
both nr-axSpA and AS patients [16]. In a follow-
up study in the same patient cohort, exercise
therapy improved global disease activity in both
AS and nr-axSpA subgroups [17].
The 2019 American College of Rheumatol-
ogy/Spondylitis Association of America/
Spondyloarthritis Research and Treatment Net-
work recommendations for patients with active
axSpA note that physical therapy is strongly
recommended, with supervised exercise being
preferred over more passive options such as
massage, ultrasound, and heat [18]. Physical
therapy and unsupervised back exercises are
also recommended for patients with active or
stable axSpA [18]. Similarly, the 2016 ASA-
S–EULAR recommendations for axSpA state that
patients should be encouraged to exercise reg-
ularly, and that physical therapy should be
considered [19].
Although treatment guidelines advocate the
inclusion of physical activity for the optimal
management of axSpA [18–21], specific guid-
ance about the amount of exercise required to
produce a beneficial effect is lacking [22]. Global
recommendations by the World Health Orga-
nization (WHO) state that all adults should
engage in at least 150 min of moderate-inten-
sity or at least 75 min of vigorous-intensity
aerobic physical activity each week or an
equivalent combination of moderate- and vig-
orous-intensity activity [23]. One study showed
that physical function, health-related quality of
life, and disease activity were improved in
patients with SpA (including those with axSpA)
who met the WHO recommendations for
physical activity [24]. However, reports suggest
that the majority of patients with axSpA fail to
meet such recommendations [25], and that
exercise levels in these patients tend to be lower
than those in the general population [22, 25].
Objective measurements of physical activity,
such as pedometers and accelerometers, track
an individual’s movement. Studies investigat-
ing physical activity in axSpA have utilized
technology-based assessments, allowing for the
use of an unbiased tool in the patient’s own
environment [26–28]. Swinnen and colleagues
measured physical activity during five consec-
utive days using ambulatory monitoring (Sen-
seWear armband) in 40 patients with axSpA and
40 age- and gender-matched healthy controls.
Patients with axSpA displayed lower physical
activity versus controls, and these differences
were not influenced by self-reported disease
activity [26]. A prospective observational study
assessed physical activity continuously over
3 months in 79 patients with axSpA using a
connected activity tracker, and disease flares
were self-assessed weekly. The authors con-
firmed that persistent flares were related to a
moderate decrease in physical activity. They
also concluded that activity trackers may give
indirect information on disease activity [27]. In
another study, the authors also showed that
wearable activity trackers allow longitudinal
assessment of physical activity in axSpA, with
only 27% of patients meeting the WHO rec-
ommendations [28]. Mobile activity trackers
appear acceptable to patients and their use
should be further explored as motivational tools
to improve physical activity in axSpA patients
[28]. In the prospective, observational ActCon-
nect study, confirmed axSpA patients had their
physical activity assessed continuously by the
number of steps per minute over 3 months
using a consumer-grade activity tracker. Flares
were assessed weekly and machine-learning
techniques were applied to the data [29].
Patient-reported flares were found to be associ-
ated with reduced physical activity [29]. Self-
management mobile health (mHealth) apps
have also been proposed to offer patients real-
time feedback to help them keep track of dis-
ease-related parameters, better adhere to medi-
cation schemes, and engage in physical therapy
[30]. Data from 31 interviews with chronic
arthritis patients showed a strong preference for
mHealth features, which enabled them to keep
better track of their condition, report these data
to their healthcare professional, and receive
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tailored information based on disease-related
health data specific to their type of arthritis [30].
However, assessment of physical activity
using subjective measurement instruments,
such as self-reported questionnaires and activity
logs [27], is more common, with validation in
healthy controls [31] (Table 1). The Short
Questionnaire to Assess Health (SQUASH),
Long-Form International Physical Activity
Questionnaire (IPAQ-LS), Questionnaire for
Arthritis Dialogue (QuAD), and Fear of Move-
ment and (Re)Injury (FOM/R[I]) beliefs, mea-
sured with the Tampa Scale for Kinesiophobia
11-item version (TSK-11), have also been
Table 1 Subjective self-reported questionnaires and tools to assess physical activity in axial spondyloarthritis
Physical activity measurement tool Description Population
used for tool
validation
Health-Enhancing Physical Activity criteria
(HEPA)
Reflects any form of physical activity that is
advantageous to the health and functional
capacity of the individual. Questionnaires such as
SQUASH are used to assess HEPA [67]
Healthy
subjects
Long-Form International Physical Activity
Questionnaire (IPAQ-LF)
31-item questionnaire assessing several different
types of physical activity (occupational,
household and gardening, transport, and leisure
time) in an average week over the past month
[31, 69]
Healthy
subjects
Patients with
axSpA
Short-Form International Physical Activity
Questionnaire (IPAQ-SF)
9-item questionnaire based on the IPAQ-LF [69]
Office in Motion Questionnaire (OIMQ) Covers domestic, work, and sports activities, with
the patient recalling the past 7 days [72]
Baecke Physical Activity Questionnaire Work, sports, and non-sports leisure activities are
assessed, with the number of months per year and
hours per week recorded [68]
Patients with
hip disorders
Short Questionnaire to Assess Health (SQUASH) Several types of activity assessed including
commuting, work and household activities, and
leisure time. Patients refer to an average week
over the past few months [31]
Healthy
subjects
Patients with
axSpA
Questionnaire for Arthritis Dialogue (QuAD) Covers beliefs about psychological factors, genetic
factors, physical activity, diet, lifestyle factors, and
miscellaneous beliefs. No timescale specified
[31, 32]
Patients with
RA or axSpA
Fear of Movement and (Re)Injury (FOM/R[I])
beliefs, measured with the Tampa Scale for
Kinesiophobia 11-item version (TSK-11)
Covers beliefs about activity limitations relative to
disease activity and spinal mobility [33]
Patients with
axSpA
axSpA axial spondyloarthritis, HEPA Health-Enhancing Physical Activity criteria, IPAQ-LF Long-Form International
Physical Activity Questionnaire, IPAQ-SF Short-Form International Physical Activity Questionnaire, OIMQ Office in
Motion Questionnaire, RA rheumatoid arthritis, SQUASH Short Questionnaire to Assess Health
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validated in axSpA [31–33]. The SQUASH and
IPAQ-LS questionnaires assess different forms of
physical activity, such as sports and domestic
activities, through patients recalling the dura-
tion/level of activity [31]. The 21-item QuAD
includes four items on physical activity [32].
Patient beliefs regarding their disease were wide
ranging. The belief that physical activity had a
negative impact on the disease was associated
with anxiety and helplessness about the disease,
and poor patient education. However, patients
with axSpA were less likely to believe that their
disease was caused by smoking, and more likely
to believe that physical activity could improve
their disease status [32]. FOM/R(I) (TSK-11) was
shown to be a promising tool to explain fearful
beliefs about activity limitations relative to
disease activity and spinal mobility in axSpA
[33].
Current Perspectives on Sleep in axSpA
Disturbed sleep, especially during the latter part
of the night, is a common problem in patients
with axSpA, leading patients to get up and walk
around to relieve the symptoms. This con-
tributes to daytime fatigue [8], which is likely to
impact the ability and willingness of patients to
engage in physical activity. It has been reported
that 54.8% of patients with AS experience sleep
disturbances [34], and patients with fatigue are
likely to have more than three awakenings in
the night and generally feel more tired the next
morning [35]. Other sleep problems that may
also occur in axSpA patients include poor sleep
quality, sleep-onset insomnia, difficulty awak-
ening, and obstructive sleep apnea syndrome
[36].
Like physical activity, the impact of axSpA
on patients’ sleep can be assessed using objec-
tive or subjective instruments [37].
Polysomnography (PSG) is the widely used
‘‘gold standard’’ objective measure of sleep,
which involves the monitoring of physical and
psychological processes in a sleep laboratory,
allowing for detailed assessment of sleep archi-
tecture and sleep-disordered breathing [38].
There are very few studies that comprehensively
investigate sleep in axSpA patients using PSG
[37, 39, 40]. It is expensive, requires monitoring
in a sleep laboratory [38], is often intrusive to
sleep [41], and is only suitable for use over short
timeframes, meaning that data and conclusions
can be misinterpreted, for example, in instances
where sleep problems do not occur every night.
Subjective measures that have been used in
axSpA are self-reported questionnaires related to
sleep, or those that include questions about
sleep with respect to general health or quality of
life, which have been validated in both healthy
controls and in those with AS or nr-axSpA (see
Table 2) [42–49].
Only one placebo-controlled study has
assessed sleep quality in patients with active
axSpA using a validated instrument; this study
investigated the efficacy of golimumab in
reducing sleep disturbance using the Jenkins
Sleep Evaluation Questionnaire (JSEQ) [8].
Treatment with golimumab resulted in signifi-
cant improvements in JSEQ scores from baseline
at week 14 and week 24 compared with placebo.
Improvements in sleep quality (as assessed by
PSG) significantly correlated with improve-
ments in Short Form-36 (SF-36), BASFI, night
back pain, BASDAI, and total back pain scores,
as well as in measures of fatigue from the BAS-
DAI and vitality from the SF-36 [8].
Objective Measures of Sleep and Physical
Activity
There is a need for objective, more convenient,
and less intrusive objective measures that would
allow for long-term assessment of sleep distur-
bances and their impact on physical activity,
and physical activity in patients’ daily lives,
outside of the clinic. Actigraphy, a technology
based on small sensors, is increasingly being
used in both interventional and non-interven-
tional studies to evaluate physical activity and
sleep. The use of mechanical movement sensors
to evaluate psychological disorders in a pedi-
atric population in the 1950s was the first
reported medical use of actigraphy [50]. Over
time, with advances in the consumer electron-
ics markets—within which consumer-grade
activity monitors have been popularized by
Fitbit and Garmin—actigraphy devices have
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become unintrusive, making them more con-
venient and suitable for continuous wear.
Modern actigraphy techniques use digital
accelerometers to measure body movements,
typically at the wrist or waist. Assessment of
data from an accelerometer typically involves
integration of acceleration data with respect to
time [10], in which continual and prolonged
actigraphic recording of daytime and nocturnal
activity provides real-time data that can be
stored long term [50]. Examples of actigraphy
traces taken from healthy controls, those with
Table 2 Subjective self-reported questionnaires and tools to assess sleep in axial spondyloarthritis [37]
Sleep measurement
tool
Description Population used for tool validation
Epworth Sleepiness
Scale (ESS)
8-item questionnaire measuring daytime
sleepiness and evaluating the possibility of
falling asleep in everyday situations [42]
Healthy controls
Patients with a range of sleep disorders
Jenkins Sleep
Evaluation
Questionnaire
(JSEQ)
4-item questionnaire measuring frequency and
severity of sleep disturbance in the past 30 days
[43]
Male air traffic controllers
Patients 6 months after cardiac surgery
Medical Outcomes
Study Sleep
questionnaire
(MOS)
12-item questionnaire assessing sleep quality and
quantity over the past month [44, 45]
Persons aged C 14 years
Pittsburgh Sleep
Quality Index
(PSQI)
19 questions measuring sleep disturbance over
the past month [46]
Healthy controls (good sleepers)
Bad sleepers (depressed, sleep disorders)
Uppsala Sleep
Inventory (USI)
80-item questionnaire measuring sleep and sleep-
related issues [47]
Healthy controls (random sample in age group
45–64 years)
Ankylosing
Spondylitis Quality
of Life Index
(ASQoL)
18-item questionnaire assessing quality of life.
One question assesses sleep; Q5 = ‘‘It’s
impossible to sleep’’ [48]
Patients with AS
Nottingham Health
Profile (NHP)
2-part questionnaire involving subjective self-
assessment of health. Part I relates to sleep [49]
Healthy controls
Selected controls (patients with minor non-
acute conditions, fracture victims, patients
with peripheral vascular disease, chronically ill
elderly, patients with osteoarthrosis, pregnant
women, ‘‘fit’’ elderly, mine-rescue workers)
Reprinted by permission from Springer, Rheumatol Int, Prevalence and factors associated with disturbed sleep in patients
with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review, S. Leverment et al. 
Springer-Verlag Berlin Heidelberg 2016
ASQoL Ankylosing Spondylitis Quality of Life Index, axSpA axial spondyloarthritis, ESS Epworth Sleepiness Scale, JSEQ
Jenkins Sleep Evaluation Questionnaire, MOS Medical Outcomes Study Sleep questionnaire, NHP Nottingham Health
Profile, PSQI Pittsburgh Sleep Quality Index, USI Uppsala Sleep Inventory
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chronic pain receiving opioid medication, and
those receiving treatment other than opioid
medication are shown in Fig. 1 [51]. Traces can
be further processed and activity levels analyzed
to quantitatively assess sleep quality, including
the determination of measures such as sleep
latency, sleep efficiency, awake times, and
awake time duration [51].
Medical-grade actigraphy devices (such as
the Actiwatch [Philips N.V.] and ActiGraph Link
GT9X [ActiGraph, LLC.]) have been used as
alternatives to PSG [52] (Fig. 2). Although acti-
graphic assessment of sleep is not comparable to
PSG for clinical diagnosis of sleep-disordered
breathing or sleep architecture–specific disor-
ders, it has been used extensively to effectively
assess more general sleep parameters [53].
Actigraphy is increasingly being used to evalu-
ate the impact of treatment interventions on
physical activity and sleep. Actigraphic assess-
ment of sleep is particularly helpful when
studying conditions such as chronic pain or
pruritus, in which sleep disruption is charac-
terized by restless movement [51, 54], and has
been shown to be an effective measure in
prospective studies assessing the impact of
treatment interventions on both daytime
physical activity and sleep in patients with
heart failure, atopic dermatitis, rheumatoid
arthritis, osteoarthritis, and other chronic dis-
eases [55–59].
Importantly, actigraphy has been used to
effectively assess the impact of rheumatic dis-
ease on physical activity, in which the rela-
tionship between flares and physical activity
has been evaluated [27]. During a 3-month
study of rheumatoid arthritis and axSpA, phys-
ical activity of 170 patients (91 with rheumatoid
arthritis, 79 with axSpA) was assessed by the
number of steps per day using an activity
tracker, while disease flares were self-assessed
using a weekly questionnaire. Results indicated
that frequent flares were shorter in duration and
related to decreases in physical activity. This
study was the first to longitudinally and objec-
tively explore the relationship between disease
activity and physical activity in axSpA [27].
Actigraphy has also been used in studies
evaluating musculoskeletal and neuropathic
pain. In one study, the impact of celecoxib on
osteoarthritis (n = 63) was assessed using
patient-reported outcomes, captured by a daily
eDiary, and actigraphy [58]. While objective
assessment of changes in physical activity
demonstrated a meaningful response to treat-
ment, self-reported questionnaires, with recall
periods of either 24 h or 1 week, were not sta-
tistically significant and subject to a larger pla-
cebo effect [58]. In another study evaluating the
effect of transdermal fentanyl on physical
activity over 16 weeks in patients with neuro-
pathic pain [60], the use of actigraphy showed a
37% increase in daytime activity levels in the
final 8 weeks of the study with treatment versus
baseline measurements.
In the rheumatology clinic, the use of US
Food and Drug Administration-approved actig-
raphy devices might provide a large volume of
invaluable real-time data that could be inte-
grated with electronic records, allowing for
continuous tracking of a patient’s well-being,
helping to guide the course of treatment in
patients with axSpA. Utilizing such data,
healthcare providers would be able to better
understand patient variability, and identify
potential opportunities to address axSpA-related
drivers of sleep disturbance and physical inac-
tivity. In conjunction with patient-reported
outcomes, actigraphy could also be used to
establish correlations between disease activity
and pain levels with daytime physical activity
and sleep.
Limitations of Assessing Physical Activity
and Sleep in axSpA
Subjective methods, such as self-reported ques-
tionnaires and logs, are the most common tools
for assessing patients’ daily physical activity and
sleep quality. Although these tools are inex-
pensive and broadly accessible to investigators,
they have limitations. Research has shown that
reporting bias [61] and patient recall [62] have
an impact on questionnaire scores. One study in
patients with axSpA showed that exertion and
pain experienced while performing activities
appeared to have a greater negative influence
on their BASFI score than their actual perfor-
mance-based measures of physical function,
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leading to reporting bias [63]. In addition, sev-
eral self-reported questionnaires used to mea-
sure physical activity and sleep in axSpA require
patient recall over 1 month [31, 37], which may
lead to inaccuracy unless a detailed diary is kept
by the patient.
Self-reported scores for physical activity do
not substitute for objective measures, and
accurate assessments should include both self-
reported and objective measures [64]. Similarly,
there is currently no validated sleep measure for
patients with axSpA, and there are inconsis-
tencies between the different sleep scales and
methods used to define ‘‘poor sleep’’ [37].
Therefore, more objective measures are needed
to allow for accurate assessment of sleep quality
in this patient population.
When considering actigraphy, although
allowing for long-term assessment of physical
activity and sleep, it can overestimate sleep and
underestimate wake time in certain patient
groups [50]. Since actigraphy technology uses
lack of movement as a proxy for sleep, those
who are awake but motionless would be classi-
fied as asleep. This would incorrectly underes-
timate the number and severity of sleep
Fig. 1 Example actigraphy traces. Black bars indicate
activity levels, with intensity on the vertical axis and time
on the horizontal axis. In this sample, actigraphy shows
continuous activity during the night in patients not on
opioid medication (blue bar/arrows) while patients on
opioid medication are least active during the night (red
bar/arrows). Figure resized from Robertson, et al. (2016)
[51].  2016 J. A. Robertson et al. Sleep disturbance in
patients taking opioid medication for chronic back pain.
Anaesthesia. 2016;71:1296-1307. Used under CC BY 4.0
Rheumatol Ther (2019) 6:487–501 495
disturbances [50]. Furthermore, while actigra-
phy is an objective measure of movement, it is
unable to detect the level of energy expenditure
or exertion related to physical activity [65].
Clinical Implications
The use of newer tools and techniques, such as
actigraphy, will contribute to the better under-
standing of sleep disturbance and physical
activity over time, and aid in the interpretation
of associated therapeutic outcomes. This will
provide healthcare providers with data to sup-
port the optimization of an individual patient’s
treatment regimen based on the knowledge
obtained from the patient themselves, aug-
mented by the information gathered from oth-
ers. With such ability and insight, it is likely
that further improvements in sleep and physical
activity may be achieved through refining
patient management and treatment, and may
allow for long-term changes in the overall
health status of these patients.
DISCUSSION AND CONCLUSIONS
Sleep disturbance secondary to pain, stiffness,
and proinflammatory mediators [66] is a major
symptom in patients with axSpA, which may
lead to impaired physical activity. Regular
physical activity is recommended in a number
of guidelines on the nonpharmacological man-
agement of axSpA [11, 18–21]; physical activity
has been shown to improve physical function,
mobility, disease activity, quality of life, and
cardiovascular performance in this group of
patients [12, 13]. However, exercise levels tend
to be lower in these patients [22, 25]. There is a
need for convenient measures that allow for the
long-term assessment of both sleep and physical
activity in patients’ daily lives. The majority of
measures for sleep and physical activity used in
this patient population are subjective and lim-
ited by patient recall, reporting bias, and rela-
tively short study intervals [31, 37, 67–69].
Actigraphy will enable unintrusive, objective
monitoring of sleep and physical activity in
patients with axSpA, over longer periods of time
[27, 53, 56–58], though further research to fully
evaluate its utility and value for use in everyday
clinical practice is needed. Importantly, actig-
raphy may be used to evaluate the impact of
treatment interventions on physical activity
and sleep. This will allow for better under-
standing of sleep disturbance and impaired
physical activity in patients with axSpA, the
recognition of patient variability, and the
identification of potential opportunities to
address axSpA-related drivers of sleep distur-
bance and physical activity.
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